Microarray-based transcriptome analyses allow for assaying thousands of genes in a single experiment [9] and have recently become available for scleractinian corals [10], [11].
The miRNA dependent reporter vector can be used to study stages of reprogramming and differentiation since it allows for assay and/or isolation of cells based upon fluorescence intensity.
CDC initially performed the testing, but on June 5, 2013, a Food and Drug Administration issued Emergency Use Authorization allowed for assay deployment in a kit to laboratories through the Laboratory Response Network.
This system offers significant advantages over the current in vitro based assays and the few available replicon models in that it allows for assay of protease cleavage upon multiple boundaries in the context of a full ORF1 polyprotein, which is temporally expressed in mammalian cells in a transient system which does not require the laborious process of establishing stable replicon cell lines.
The format of this tool box is flexible, and it allows for assays and tests to be added as deemed necessary based on new insights or developments.
These experiments could be carried out in microfluidic chips that were patterned in parallel, allowing for assays on multiple cell types, drugs, cytokines, and shear rates simultaneously using a single sample of a patient's blood.
Drug targets for many pathogenic microbes such as Mycobacterium tuberculosis or Plasmodium falciparum are often selected from proteins identified through genome sequencing efforts, for which enzymatic function is already known allowing for biochemical assay development in drug screening.
The IFOBT also allows for quantitative assay, and the positivity threshold may be adjusted to fit the local clinical and/or economic setting.
This study introduces an approach for protein biomarker development to the OA field, which allows for rapid assay development, SRM mass spectrometry, to identify tryptic peptides representative of target proteins.
